# EDGAR Filing Document

**Accession Number:** 0001561921
**File Stem:** 0001104659-25-076232
**Filing Date:** 2025-8
**Character Count:** 32031
**Document Hash:** f8f57392c26ca881ae318b6897e987e0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-076232.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001104659-25-076232

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**EFFECTIVENESS DATE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TELA Bio, Inc.
- **CENTRAL INDEX KEY:** 0001561921
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455320061
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289497
- **FILM NUMBER:** 251202999

**BUSINESS ADDRESS:**
- **STREET 1:** 1 GREAT VALLEY PARKWAY, SUITE 24
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 484-320-2930

**MAIL ADDRESS:**
- **STREET 1:** 1 GREAT VALLEY PARKWAY, SUITE 24
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**As filed with the United States Securities and Exchange Commission on August 11, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**TELA BIO, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **45-5320061** |
| (State or other jurisdiction of incorporation or<br> organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **1 Great Valley Parkway, Suite 24<br> Malvern, Pennsylvania** | **19355** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**TELA BIO, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN**

(Full title of the plan)

**Antony Koblish<br> Chief Executive Officer<br> TELA Bio, Inc.<br> 1 Great Valley Parkway, Suite 24**

**Malvern, Pennsylvania 19355**

(Name and address of agent for service)

**(484) 320-2930**<br> (Telephone number, including area code, of agent for service)

***Copies to:***

Rachael M. Bushey, Esq.<br> Justin S. Platt, Esq.<br> Goodwin Procter LLP

3025 John F Kennedy Blvd<br> Philadelphia, PA 19104<br> (445) 207-7805

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

On April 3, 2025, the Board of Directors of TELA Bio, Inc. (the "<u>Company</u>") adopted, subject to approval by the stockholders, an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan (the "<u>Equity Plan</u>") (such amendment, the "<u>Amendment</u>" and the Equity Plan, after giving effect to the Amendment, the "<u>Amended Equity Plan</u>"), which the stockholders of the Company approved at the Company's 2025 Annual Meeting of Stockholders held on May 28, 2025. The Amendment increased the number of shares of common stock, par value $0.001 per share, of the Company ("<u>Common Stock</u>"), authorized for issuance thereunder by 3,500,000 shares of Common Stock (the "<u>Additional Shares</u>"). This Registration Statement on Form S-8 (the "<u>Registration Statement</u>") is being filed solely for the purpose of registering the Additional Shares for issuance under the Amended Equity Plan.

Such Additional Shares are of the same class of securities as the shares of Common Stock issuable under the Equity Plan for which the currently effective Registration Statements on Form S-8 (File Nos. [333-235241](https://www.sec.gov/Archives/edgar/data/1561921/000110465919066854/a19-23526_1s8.htm) and [333-245707](https://www.sec.gov/Archives/edgar/data/1561921/000110465920094784/tm2026521d1_s8.htm)) filed with the Securities and Exchange Commission (the "<u>Commission</u>") on November 25, 2019 and August 8, 2020, respectively (the "<u>Prior Registration Statements</u>"), were filed. Upon the effectiveness of this Registration Statement, an aggregate of 7,432,620 shares of Common Stock will be registered for issuance from time to time under the Amended Equity Plan, inclusive of the Additional Shares. Pursuant to General Instruction E of Form S-8 regarding registration of Additional Securities, the contents of the Prior Registration Statements are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Prior Registration Statement are presented herein.

**PART II<br> INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.** 

The following documents, which have been filed by the Registrant with the Commission are incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) [The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 21, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1561921/000155837025003460/tela-20241231x10k.htm) (the "2024 10-K");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Registrant's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on [May 8, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1561921/000155837025006994/tela-20250331x10q.htm) and [August 11, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1561921/000155837025011052/tela-20250630x10q.htm);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [The Registrant's Definitive Proxy Statement on Schedule 14A filed with the Commission on April 17, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1561921/000110465925036020/tm252403-3_def14a.htm), to the extent incorporated by reference into the 2024 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Registrant's Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed with the Commission on[March 31, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1561921/000110465925029612/tm2510876d1_8k.htm), [May 30, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1561921/000110465925054867/tm2516546d1_8k.htm) and [June 2, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1561921/000110465925055248/tm2516546d2_8k.htm).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The description of the Registrant's Common Stock contained in the Registrant's Registration Statement on [Form 8-A filed with the Commission on November 7, 2019 (File No. 001-39130)](https://www.sec.gov/Archives/edgar/data/1561921/000110465919060945/a19-16745_118a12b.htm), together with any amendment thereto filed with the Commission for the purpose of updating such description; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

**Item 8.** **Exhibits.** 

The following documents are filed as exhibits to this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description of Exhibit** |
| [3.1](https://www.sec.gov/Archives/edgar/data/1561921/000110465919065432/a19-23314_1ex3d1.htm) | [Fourth Amended and Restated Certificate of Incorporation of TELA Bio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-39130) filed on November 19, 2019).](https://www.sec.gov/Archives/edgar/data/1561921/000110465919065432/a19-23314_1ex3d1.htm) |
| [3.2](https://www.sec.gov/Archives/edgar/data/1561921/000155837025011052/tela-20250630xex3d1.htm) | [Certificate of Amendment to TELA Bio, Inc.'s Fourth Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q (File No. 001-39130) filed on August 11, 2025).](https://www.sec.gov/Archives/edgar/data/1561921/000155837025011052/tela-20250630xex3d1.htm) |
| [3.3](https://www.sec.gov/Archives/edgar/data/1561921/000155837023018822/tela-20230930xex3d1.htm) | [Third Amended and Restated Bylaws of TELA Bio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q (File No. 001-39130) filed on November 13, 2023).](https://www.sec.gov/Archives/edgar/data/1561921/000155837023018822/tela-20230930xex3d1.htm) |
| [4.1](https://www.sec.gov/Archives/edgar/data/1561921/000104746919005938/a2239923zex-4_1.htm) | [Form of Certificate of Common Stock (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1 (File No. 333-234217) filed on October 29, 2019).](https://www.sec.gov/Archives/edgar/data/1561921/000104746919005938/a2239923zex-4_1.htm) |
| [5.1\*](tm2522741d1_ex5-1.htm) | [Opinion of Goodwin Procter LLP as to the legality of the securities being registered.](tm2522741d1_ex5-1.htm) |
| [23.1\*](tm2522741d1_ex23-1.htm) | [Consent of KPMG LLP, independent registered public accounting firm for TELA Bio, Inc.](tm2522741d1_ex23-1.htm) |
| [23.2\*](tm2522741d1_ex5-1.htm) | [Consent of Goodwin Procter LLP (contained in Exhibit 5.1).](tm2522741d1_ex5-1.htm) |
| [24.1\*](#a_001) | [Power of Attorney (included on the signature page of the Registration Statement).](#a_001) |
| [99.1#](https://www.sec.gov/Archives/edgar/data/1561921/000110465920070850/tm2021946d1_ex10-1.htm) | [TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan (incorporated by reference to exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 8, 2020).](https://www.sec.gov/Archives/edgar/data/1561921/000110465920070850/tm2021946d1_ex10-1.htm) |
| [99.2\*](tm2522741d1_ex99-2.htm) | [Amendment No. 1 to TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan.](tm2522741d1_ex99-2.htm) |
| [99.3#](https://www.sec.gov/Archives/edgar/data/1561921/000155837022008301/tela-20220331xex10d1.htm) | [Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Stock Option Grant Notice and Stock Option Agreement (incorporated by reference to exhibit 10.1 to the Company's Quarterly Report on Form 10-Q, filed on May 11, 2022).](https://www.sec.gov/Archives/edgar/data/1561921/000155837022008301/tela-20220331xex10d1.htm) |
| [99.4#](https://www.sec.gov/Archives/edgar/data/1561921/000155837022008301/tela-20220331xex10d2.htm) | [Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (time-based vesting) (incorporated by reference to exhibit 10.2 to the Company's Quarterly Report on Form 10-Q, filed on May 11, 2022).](https://www.sec.gov/Archives/edgar/data/1561921/000155837022008301/tela-20220331xex10d2.htm) |
| [99.5#](https://www.sec.gov/Archives/edgar/data/1561921/000155837023004468/tela-20221231xex10d13.htm) | [Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (performance-based vesting) (incorporated by reference to exhibit 10.13 to the Company's Annual Report on Form 10-K, filed on March 23, 2023).](https://www.sec.gov/Archives/edgar/data/1561921/000155837023004468/tela-20221231xex10d13.htm) |
| [107\*](tm2522741d1_ex-filingfees.htm) | [Filing Fee Table.](tm2522741d1_ex-filingfees.htm) |

---

\* Filed herewith <br> # Denotes management contract or compensatory plan or arrangement

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of Malvern, Commonwealth of Pennsylvania, on August 11, 2025.

---

| | |
|:---|:---|
| **TELA BIO, INC.** | **TELA BIO, INC.** |
| By: | /s/ Antony Koblish |
|  | Antony Koblish |
|  | *Chief Executive Officer and Director* |

---

**POWER OF ATTORNEY**

*KNOW ALL PERSONS BY THESE PRESENTS*, that each person whose signature appears below hereby constitutes and appoints each of Antony Koblish and Roberto Cuca as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Antony Koblish | Chief Executive Officer and Director | August 11, 2025 |
| Antony Koblish | (Principal Executive Officer) |  |
| /s/ Roberto Cuca | Chief Operating Officer and Chief Financial Officer | August 11, 2025 |
| Roberto Cuca | (Principal Financial Officer) |  |
| /s/ Megan Smeykal | Chief Accounting Officer and Controller | August 11, 2025 |
| Megan Smeykal | (Principal Accounting Officer) |  |
| /s/ Doug Evans | Chairman, Board of Directors | August 11, 2025 |
| Doug Evans |  |  |
| /s/ Kurt Azarbazin | Director | August 11, 2025 |
| Kurt Azarbazin |  |  |
| /s/ Vince Burgess | Director | August 11, 2025 |
| Vince Burgess |  |  |
| /s/ Lisa Colleran | Director | August 11, 2025 |
| Lisa Colleran |  |  |
| /s/ Federica O'Brien | Director | August 11, 2025 |
| Federica O'Brien |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm2522741d1_ex5-1img001.jpg) | Goodwin Procter LLP |
| ![](tm2522741d1_ex5-1img001.jpg) | 3025 John F Kennedy Blvd |
| ![](tm2522741d1_ex5-1img001.jpg) | Philadelphia, PA 19104 |
| ![](tm2522741d1_ex5-1img001.jpg) |  |
| ![](tm2522741d1_ex5-1img001.jpg) | goodwinlaw.com |
| ![](tm2522741d1_ex5-1img001.jpg) | +1 445 207 7800 |

---

August 11, 2025

TELA Bio, Inc.

1 Great Valley Parkway, Suite 24

Malvern, PA 19355

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 3,500,000 shares (the "Shares") of Common Stock, par value $0.001 per share ("Common Stock"), of TELA Bio, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan, as amended by the Amendment No. 1, dated as of May 28, 2025 (collectively, the "2019 Plan").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the 2019 Plan, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Goodwin Procter llp

GOODWIN PROCTER LLP

## Exhibit 23.1

**Exhibit 23.1**

![](tm2522741d1_ex23-1img001.jpg)

KPMG LLP

Suite 4000

1735 Market Street

Philadelphia, PA 19103-7501

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 21, 2025, with respect to the consolidated financial statements of TELA Bio, Inc. and subsidiaries, incorporated herein by reference.

/s/ KPMG LLP

Philadelphia, Pennsylvania

August 11, 2025

## Exhibit 99.2

**Exhibit 99.2**

**TELA BIO, INC.**

**AMENDMENT NO. 1 TO**

**AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN**

WHEREAS, the Board of Directors of TELA Bio, Inc., a Delaware corporation (the "**Company**") approved and adopted the Amended and Restated 2019 Equity Incentive Plan (the "**2019 Plan**") of the Company on April 20, 2020; and

WHEREAS, the Board of Directors and the stockholders of the Company have determined that it is in the best interest of the Company to amend the 2019 Plan as set forth in this Amendment No. 1 (this "**2019 Plan Amendment**").

NOW, THEREFORE, the 2019 Plan is amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;**1.**  **<u>Amendment of the 2019 Plan</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **1.01.** Section 1(h) of the 2019 Plan is hereby amended and restated in its entirety to read as follows:

"(h) "Change in Control" shall mean the occurrence of any of the following events: (i) any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) is or becomes a "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total power to vote for the election of directors of the Company; (ii) during any twelve month period, individuals who at the beginning of such period constitute the Board and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Section 1(h)(i), Section 1(h)(iii), Section 1(h)(iv) or Section 1(h)(v) hereof) whose election by the Board or nomination for election by the Company's stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period of whose election or nomination for election was previously approved, cease for any reason to constitute a majority thereof; (iii) the merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to 50% or more of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); (iv) the sale or other disposition of all or substantially all of the assets of the Company; or (v) a liquidation or dissolution of the Company.

Notwithstanding anything in the Plan or an Award Agreement to the contrary, if an Award is subject to Section 409A of the Code, no event that, but for the application of this paragraph, would be a Change in Control as defined in the Plan or the Award Agreement, as applicable, shall be a Change in Control unless such event is also a "change in control event" as defined in Section 409A of the Code."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **1.02.** Section 3(a) of the 2019 Plan is hereby amended and restated in its entirety to read as follows:

"(a) <u>Shares Subject to the Plan</u>. Subject to adjustments as provided in <u>Section 3(c)</u> of the Plan, the maximum number of shares that may be issued in respect of Awards under the Plan is 7,432,620 Shares (the "<u>Plan Limit</u>"), all of which Shares may be issued in respect of Incentive Stock Options. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded (under this Plan and all other cash compensation paid by the Company) to any Participant in his or her capacity as a Non-Employee Director in any single calendar year shall not exceed $1,000,000 in the first calendar year an individual becomes a Non-Employee Director and (ii) $750,000 in any other calendar year. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC Topic 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **1.03.** Section 3(b) of the 2019 Plan is hereby amended and restated in its entirety to read as follows:

"(b) Effect of the Expiration or Termination of Awards. If and to the extent that an Option or a Stock Appreciation Right expires, terminates or is cancelled or forfeited for any reason without having been exercised in full, the Shares associated with that Award will again become available for grant under the Plan. Similarly, if and to the extent an Award of Restricted Stock or Restricted Stock Units is canceled or forfeited for any reason, the Shares subject to that Award will again become available for grant under the Plan. Notwithstanding the foregoing, the following Shares shall not be added to the Shares authorized for grant under the Plan: (i) Shares tendered or held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding and (ii) Shares subject to a Stock Appreciation Right that are not issued in connection with the stock settlement of the Stock Appreciation Right upon exercise thereof. In the event the Company repurchases Shares on the open market, such Shares shall not be added to the Shares available for issuance under the Plan."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **1.04.** Section 19 of the 2019 Plan is hereby amended and restated in its entirety to read as follows:

"<u>Section 19. Term of the Plan.</u> Unless the Plan shall theretofore have been terminated in accordance with Section 11, the Plan shall terminate on the 10-year anniversary of April 3, 2025, and no Awards under the Plan shall thereafter be granted."

&nbsp;&nbsp;&nbsp;&nbsp;**2.**  **<u>Miscellaneous</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.01.** <u>Effect</u>. Except as amended hereby, the 2019 Plan shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.02.** <u>Defined Terms</u>. All capitalized terms used but not specifically defined herein shall have the same meanings given such terms in the 2019 Plan unless the context clearly indicates or dictates a contrary meaning.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.03.** <u>Governing Law</u>. This Amendment shall be governed by and construed in accordance with the laws and judicial decisions of the State of Delaware, without regard to the application of the principles of conflict of laws.

---

| | |
|:---|:---|
| **ADOPTED BY BOARD OF DIRECTORS:** | **April 3, 2025** |
| **APPROVED BY STOCKHOLDERS:** | **May 28, 2025** |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **TELA Bio, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.001 par value per share | 457(a) | 3500000 | $1.74 | $6090000.00 | 0.0001531 | $932.38 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $6090000.00  |  | $932.38  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $932.38  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 also covers an indeterminate number of additional shares of common stock, par value per share $0.001 (the "Common Stock"), of TELA Bio, Inc. (the "Registrant") issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock of the Registrant. (2) Represents shares of Common Stock that are issuable under the Amendment No. 1 to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan, which was adopted by the Registrant's Board of Directors on April 3, 2025 and approved by the Registrant's stockholders at the 2025 Annual Meeting of Stockholders on May 28, 2025. (3) Estimated pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share and proposed maximum offering price are based upon the average of the high and low prices of the Common Stock as reported on The Nasdaq Global Market on August 8, 2025.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---